

OBJECTIVES: The objective of this study was to estimate Incremental Cost-Effectiveness Ratio (ICER) of utilizing eribulin against Treatment of Physician's Choice (TPC) for third line treatment of Metastatic Breast Cancer (MBC) in Taiwan. **METHODS:** Efficacy and safety data was obtained from a multicentre phase III clinical trial (EMBRACE) comparing eribulin against TPC. A five-year partitioned survival cost-effectiveness analysis (CEA) with a Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) as the effectiveness measure was developed. Costs included in the model were drugs & administration, post-treatment resource use, toxicity management and indirect treatment costs. Cost effectiveness was evaluated using the Gamma distribution for Overall Survival (OS), Weibull for Progression Free Survival (PFS), response duration and, toxicity time. Health state utilities were applied to each component and aggregated. In base-case analysis, 3% discounting was applied for both benefits and costs. Deterministic sensitivity analysis was used to evaluate sensitivity of the key variables. **RESULTS:** OS based on Gamma extrapolation was 17.26 months in eribulin group versus 14.39 months in TPC group for a difference of 2.87 months. Mean time without progressive disease was 4.68 months for eribulin and 3.96 months for TPC for a difference of 0.72 months. The Quality Adjusted Life Years were 0.83 in the eribulin group compared to 0.70 in TPC group for a mean incremental improvement of 0.13 years. Treatment costs were NTD 351,875 for eribulin and NTD 113,552 for TPC for a difference of NTD 238,323. In base-case analysis, the ICER with discounting was NTD 1,823,482. Survival time was most sensitive variables on the ICER in this CEA. **CONCLUSIONS:** With an ICER of NTD 1,823,482 compared to TPC, eribulin was found to be cost-effective in third and later line MBC population in Taiwan. Given the limited number of effective therapeutic options available to these patients, eribulin represents a valid option for optimizing treatment pathways.

PCN137

AFLIBERCEPT IN COMBINATION WITH FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: COST-EFFECTIVENESS BASED ON VELOUR BEST EFFICACY SUBGROUP POST-HOC ANALYSIS

Echave M¹, Oyağüz I¹, Lamas MJ², Rubio M³, Subirà R³

¹Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, ²Complejo Hospitalario de Santiago de Compostela, Santiago de Compostela, Spain, ³Sanofi, Barcelona, Spain

OBJECTIVES: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) in Best Efficacy Subgroup (BES) patients previously treated with oxaliplatin compared to FOLFIRI. **METHODS:** A post-hoc analysis of the VELOUR clinical trial revealed an improvement of aflibercept efficacy in a specific subgroup. BES was composed by patients with performance status (PS) 0 with any number of metastatic sites or PS 1 with <2 metastatic sites, exclusive of adjuvant fast relapsers. A Markov model with 3 health states (stable disease, progression and death) was used to estimate lifetime costs and outcomes (2-weeks cycle duration). Transition from stable disease to progression implied the interruption of second-line treatment and administration of a third-line chemotherapy (72%) or best supportive care (28%). According to the National Health System (NHS) perspective only direct costs were considered. Cost estimation (€; 2015) included pharmaceutical and administration cost, adverse event management and hospital and medical visits consumption. Ex-factory price with mandatory deduction was applied for drug cost estimation. Costs and outcomes were 3% annually discounted. Sensitivity analyses (SA) were performed. **RESULTS:** Administration of aflibercept + FOLFIRI as second-line treatment on BES was more effective than FOLFIRI, yielding 1.92 LYG (23 life-months gained) compared to 1.55 LYG (18.6 months). Aflibercept + FOLFIRI accounted a total cost of €40,449, compared to €25,698 estimated for FOLFIRI. The incremental cost-effectiveness analysis provided a €33,373/LYG ratio for aflibercept in combination with FOLFIRI versus FOLFIRI for BES. SA results confirmed the model robustness. **CONCLUSIONS:** According to a post-hoc analysis, aflibercept in combination with FOLFIRI could increase overall survival versus FOLFIRI on BES. Aflibercept + FOLFIRI could be an efficient strategy for second-line treatment in specific mCRC patients for the Spanish NHS.

PCN138

COST-EFFECTIVENESS OF CARDIOPROTECTIVE EFFECT OF DEXRAZOXANE (CARDIOXANE®) IN ADVANCED/METASTATIC BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINE-BASED CHEMOTHERAPY IN MÉXICO

Paladio-Hernández JÁ¹, Martínez-Morales J²

¹Independent Consultant, Cuautitlán Izcalli, Mexico, ²UACH, Hidalgo del Parral, Mexico

OBJECTIVES: The problem of anthracycline-induced clinical heart failure is an important public health concern as it may not be seen for many years and remains a life-long threat. We performed a cost-effectiveness analysis of the cardioprotective effect of Dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy in México. **METHODS:** A decision tree model was developed in order to compare dexrazoxane with no treating. The time horizon was one year. The main data for dexrazoxane efficacy (surgery requirement and functional loss) was obtained from two open label non-comparative studies. Main costs taken into account were the drug costs, administration and monitoring and surgical costs. **RESULTS:** Dexrazoxane may lead to important savings for the Mexican public health system when it is compared to no treating. The results derived from the model indicate that Dexrazoxane is associated with less cardiac events (39% versus 13%, $P < 0.001$) and a lower and less severe incidence of congestive heart failure (11% versus 1%, $P < 0.05$) which represent a saving of 200,000 USD per patient treated. Tumor response rate was unaffected by dexrazoxane therapy. The frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions. **CONCLUSIONS:** Dexrazoxane is a dominant alternative vs no treating since it significantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efficacy of the chemotherapeutic regimen at a lower cost than no treating

PCN139

COST-EFFECTIVENESS ANALYSIS OF NEO-ADJUVANT PERTUZUMAB THERAPY IN WOMEN WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY HER2-POSITIVE BREAST CANCER IN ITALY

Pradelli L¹, Bellone M¹, Era S², Campagnoli E²

¹AdRes Srl, Torino, Italy, ²Roche Spa, Monza (MB), Italy

OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of pertuzumab in combination with trastuzumab and docetaxel as neo-adjuvant treatment for locally advanced, inflammatory, or early stage breast cancers that overexpress Human Epidermal growth factor Receptor 2 (HER2), from the Italian National Health System (SSN) perspective. **METHODS:** A six state Markov model was used to estimate outcomes and costs over a 50-year time horizon. Patients were assumed to receive standard neo-adjuvant therapy containing trastuzumab and docetaxel or the same regimen plus pertuzumab. Transition probabilities to progressive disease and death were based on total pathological complete response (pCR) rates observed in the NeoSphere study. A second analysis was carried out in which progression-free survival (PFS) was directly modelled on observed data. Expected survival was adjusted by utility weights for health states derived from literature. Direct medical unit costs were collected from official and published Italian sources. Costs and health gains were discounted at an annual 3% rate. Probabilistic sensitivity analysis (PSA) was carried out to evaluate uncertainty. **RESULTS:** Pertuzumab combination was associated with increased QALYs and costs relative to standard neo-adjuvant regimen. Acquisition drug cost of pertuzumab was the primary contributor to the difference in costs, partially offset through the prevention of relapse and worsening. The estimated ICERs range between € 3,000 and € 19,000 per QALY. In PSA, pertuzumab combination has very high probability of being cost effective relative to standard regimen for a WTP threshold of € 40,000 per QALY gained. **CONCLUSIONS:** Breast cancer with HER2 overexpression is associated with increased tumour aggressiveness, higher rates of recurrence and mortality. In the neo-adjuvant setting, pertuzumab in combination with trastuzumab and docetaxel is expected to be more effective (increased probability to reach higher pCR rate and longer PFS) than standard regimen, at a favourable cost per QALY gained.

PCN140

A COST UTILITY ANALYSIS OF CETUXIMAB FOR 1ST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER: A SUMMARY OF THE SUBMISSION TO ALL WALES MEDICINES STRATEGY GROUP (AWMSG)

Hnoosh A¹, Harty GT², Sullivan L², Byrne B², von Honhorst P³

¹Merck Serono Ltd., FELTHAM, UK, ²Merck Serono, London, UK, ³Merck KGaA, Darmstadt, Germany

OBJECTIVES: Colorectal cancer is the third most common cancer in Wales, with 2444 new cases reported in 2012. Incidence increased by 28.5% between 2002 and 2012. While survival rates in colorectal cancer are improving globally, the UK continues to lag behind other major economies. Recent evidence demonstrates that cetuximab can result in significant life extension when added to chemotherapy as a first line treatment of RAS wild type metastatic colorectal cancer. At present, cetuximab is funded in Wales mainly through Individual Patient Treatment Requests which are increasing in number due to the rising demand from both patients and physicians. An evidence submission was submitted to AWMSG to highlight this clinical benefit and assess the cost effectiveness of cetuximab. **METHODS:** An economic model was developed to assess the cost effectiveness of cetuximab in the management of unresectable RAS wt metastatic colorectal cancer in comparison to comparators available in the Welsh NHS; FOLFOX, FOLFIRI, or CAPOX alone. This includes a small population of patients with metastases confined to the liver who may subsequently be eligible for curative resection after treatment with cetuximab plus chemotherapy. The time horizon is 10 years and the discount rate applied to both outcomes and costs is 3.5%. Cetuximab Welsh Patient Access Scheme (WPAS) price was used in all analyses and the dose was set to fortnightly dosing as typically prescribed in Wales. **RESULTS:** Economic analyses estimated an incremental cost effectiveness ratio of £29,512 per QALY gained for cetuximab + FOLFOX compared to FOLFOX alone and £35,731 per QALY gained for cetuximab + FOLFIRI compared to FOLFIRI alone. **CONCLUSIONS:** These analyses demonstrate that cetuximab is a cost effective treatment and a good use of NHS Wales resources through stratification of RAS wild type patients who are likely to respond to treatment and offer patients a life-extending treatment option.

PCN141

THE COST EFFECTIVENESS OF IDELALISIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA IN ENGLAND AND WALES

Sullivan W¹, Hadlow S², Perard R³, Mealing S⁴, Cox L¹, Lee D⁵

¹BresMed Health Solutions, Sheffield, UK, ²Gilead Sciences Ltd, London, UK, ³Gilead Sciences Europe Ltd, Uxbridge, UK, ⁴ICON Health Economics and Epidemiology, Oxford, UK, ⁵BresMed, Sheffield, UK

BACKGROUND: In September 2014 the European Commission granted marketing authorisation for idelalisib with rituximab (I+R) for the treatment of chronic lymphocytic leukaemia (CLL) in previously treated patients and treatment-naïve patients with a 17p deletion or TP53mutation. **OBJECTIVES:** This study evaluated the cost effectiveness of I+R in previously-treated patients according to their eligibility for chemo-immunotherapy in England and Wales. **METHODS:** A 5-state Markov model was constructed from a National Health Service (NHS) perspective over a lifetime horizon. Study 116 contained 220 patients for whom chemo-immunotherapy was unsuitable owing to poor previous response to such treatment, the presence of 17p deletion or TP53mutation, or their fitness, randomised 1:1 to I+R (intervention) or rituximab with placebo (comparator). Intervention-arm data from Study 116 were used to inform the effectiveness of I+R in terms of response, time on treatment, progression-free and overall survival. Comparator-arm data from Study 116 were used to inform the effectiveness of (i) rituximab monotherapy, and using further assumptions, (ii) ofatumumab monotherapy and